MyMyelomaTeam

Elrexfio (elranatamab-bcmm) is a relatively newer treatment option for myeloma, so firsthand experiences shared on MyMyelomaTeam may still be growing. Here's what is known about it medically:

It was FDA-approved in August 2023 for relapsed or refractory myeloma in adults who have already tried at least four prior Show Full Answer

Elrexfio (elranatamab-bcmm) is a relatively newer treatment option for myeloma, so firsthand experiences shared on MyMyelomaTeam may still be growing. Here's what is known about it medically:

It was FDA-approved in August 2023 for relapsed or refractory myeloma in adults who have already tried at least four prior treatments, including:

- A proteasome inhibitor
- An immunomodulatory agent
- An anti-CD38 monoclonal antibody In clinical trials, Elrexfio showed an overall response rate of 58%, which is encouraging for a heavily pre-treated group.

It's given as a subcutaneous (under the skin) injection and works by targeting myeloma cells and directing your immune system's T cells to destroy them.

One practical advantage is that, unlike some other therapies, it's an "off-the-shelf" treatment — meaning it doesn't need to be custom-made for each person, so it's generally more accessible and quicker to get.

It's always worth discussing with your care team whether Elrexfio might be a suitable option for your specific situation, including any potential side effects to watch for.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

What Is BCMA-Targeted Immunotherapy? (VIDEO)